Last edition
News about Global Pharma
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849
IDEAYA Biosciences has secured an exclusive global license (outside China) from Jiangsu Hengrui Pharmaceuticals for SHR-4849, a novel DLL3-targeting ADC program with promising early clinical results in solid tumours, including small cell lung cancer.
Global Pharma | 30/12/2024 | By Manvi | 241
Hoth Therapeutics Partners with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics, Inc., a biopharmaceutical company, has secured an exclusive patent license agreement with the US Department of Veterans Affairs and Emory University for groundbreaking technology targeting obesity and related health conditions.
Global Pharma | 27/12/2024 | By Manvi | 121
AusperBio Bags USD 73 Million in Series B Financing for Chronic Hepatitis B
This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction.
Global Pharma | 27/12/2024 | By Aishwarya | 288
Meiji Seika Pharma Establishes Local Subsidiary Taiwan Meiji Pharma
Meiji Seika Pharma aims to become ‘a company in Asia in the field of infectious diseases’ as part of the ‘Meiji Group 2026 Vision’ targeting the year 2026.
Global Pharma | 26/12/2024 | By Aishwarya | 707
Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia
Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.
Global Pharma | 26/12/2024 | By Abha | 1033
Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS
RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.
Global Pharma | 26/12/2024 | By Aishwarya | 684
Porton Pharma Solutions and Dragon Sail Pharmaceutical Partner to Advance ADC Drug Ecosystem
This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC).
Global Pharma | 24/12/2024 | By Manvi | 666
At Stand E97 , the company will highlight its efforts to meet growing demand for sophisticated vials, bellow bottles and cleanroom-produced multilayer blown films, and also showcase products from its existing portfolio of healthcare packaging solutions.
Global Pharma | 24/12/2024 | By Manvi | 438
Ellipses Introduces Pioneering Clinical Trial Programme in Middle East
The trial will focus on Ellipses' next generation selective RET inhibitor (SRI), EP0031/A400, a potential treatment of RET-altered tumours, most prevalent in non-small cell lung cancer and thyroid cancer.
Global Pharma | 24/12/2024 | By Aishwarya | 306
PTC Therapeutics Submits NDA for Vatiquinone to FDA
The vatiquinone NDA is based on data from the placebo-controlled MOVE-FA study as well as results from two long-term studies including pediatric and adult FA patients.
Global Pharma | 24/12/2024 | By Aishwarya | 398
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy